Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters

Melling, Nathaniel; Thomsen, Erik; Tsourlakis, Maria Christina; Kluth, Martina; Hube-Magg, Claudia; Minner, Sarah; Koop, Christina; Graefen, Markus; Heinzer, Hans; Wittmer, Corinna; Sauter, Guido; Wilczak, Waldemar; Huland, Hartwig; Simon, Ronald; Schlomm, Thorsten; Steurer, Stefan; Krech, Till
November 2015
Carcinogenesis;Nov2015, Vol. 36 Issue 11, p1333
Academic Journal
Enhancer of zeste homolog 2 (EZH2) plays an important role in tumor development and progression by interacting with histone and nonhistone proteins. In the current study, we analyzed prevalence and prognostic impact of EZH2 in prostate cancer. EZH2 expression was analyzed by immunohistochemistry on a tissue microarray containing more than 12 400 prostate cancer specimens. Results were compared to tumor phenotype, biochemical recurrence and molecular subtypes defined by ERG status as well as genomic deletions of 3p, 5q, 6q and PTEN. EZH2 immunostaining was detectable in 56.6% of 10 168 interpretable cancers and considered strong in 1.1%, moderate in 12.2% and weak in 43.3% of cases. High EZH2 expression was strongly associated with high Gleason grade (P < 0.0001), advanced pathological tumor stage (P < 0.0001), positive nodal status (P < 0.0001), elevated preoperative PSA level (P = 0.0066), early PSA recurrence (P < 0.0001) and increased cell proliferation P < 0.0001). High-level EZH2 staining was also associated with TMPRSS2:ERG rearrangement and ERG expression in prostate cancers (P < 0.0001) and was linked to deletions of PTEN, 6q15, 5q21 and 3p13 (P < 0.0001 each) particularly in ERG-negative cancers. The prognostic impact of EZH2 was independent of established pre- and postoperatively assessed clinicopathological parameters. EZH2 has strong prognostic impact in prostate cancer and might contribute to the development of a fraction of genetically instable and particularly aggressive prostate cancers. EZH2 analysis might therefore be of clinical value for risk stratification of prostate cancer.


Related Articles

  • MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma. Jia Guo; Min Wang; Xiuheng Liu // Journal of Experimental & Clinical Cancer Research (17569966);9/4/2015, Vol. 34 Issue 1, p1 

    Elucidation of the downstream targets regulated by the metastasis-suppressive miRNAs can shed light on the metastatic processes in prostate cancer (PCa). We conducted microarray analyses and found that miR-195 was significantly decreased in metastatic PCa. Low miR-195 expression is an...

  • EZH2 overexpression as a biomarker of poor prognosis in prostate cancer. Xiaobin Gu; Xian-Shu Gao; Yun Bai; Ming Cui; Wei Xiong; Linjun Han; Wei Guo; Mu Xie; Chuan Peng; Mengmeng Su // International Journal of Clinical & Experimental Medicine;2016, Vol. 9 Issue 11, p21829 

    A number of studies have investigated the prognostic role of enhancer of zeste homolog 2 (EZH2) expression for patients with prostate cancer (PCa), however, the results were controversial. The current study was aimed to comprehensively explore the association between EZH2 and clinical outcomes...

  • Risk stratification of prostate cancer patients based on EPS-urine zinc content. Medarova, Zdravka; Ghosh, Subrata K.; Vangel, Mark; Drake, Richard; Moore, Anna // American Journal of Cancer Research;2014, Vol. 4 Issue 4, p385 

    The early detection of prostate cancer is a life-saving event in patients harboring potentially aggressive disease. With the development of malignancy there is a dramatic reduction in the zinc content of prostate tissue associated with the inability of cancer cells to accumulate the ion. In the...

  • Stromal factors involved in human prostate cancer development, progression and castration resistance. Eiro, Noemi; Fernandez-Gomez, Jesus; Sacristán, Raquel; Fernandez-Garcia, Belen; Lobo, Beatriz; Gonzalez-Suarez, Jorge; Quintas, Alejandro; Escaf, Safwan; Vizoso, Francisco // Journal of Cancer Research & Clinical Oncology;Feb2017, Vol. 143 Issue 2, p351 

    Purpose: To detect new predictive markers from the prostate cancer tissue, to study the expression by cultured cancer-associated fibroblasts (CAFs) of stromal factors implicated in prostate carcinogenesis, and to compare their expressions in localized, metastatic, castration-sensitive (CSCP),...

  • The expression and functional role of FOX transcription factor FOXJ1 in prostate cancer. Qi An; Dezhong Liu; Lian Zou // International Journal of Clinical & Experimental Medicine;2017, Vol. 10 Issue 1, p285 

    As one common malignant tumor in male reproductive-urinary system, the incidence of prostate cancer is increasing rapidly. Recent study revealed the participation of FOX transcription factor family in tumor occurrence and progression. FOXJ1, one member of FOX family, plays an important role in...

  • Prostate specific G protein coupled receptor is associated with prostate cancer prognosis and affects cancer cell proliferation and invasion. Wenqing Cao; Faqian Li; Yao, Jorge; Jiangzhou Yu; Cao, Wenqing; Li, Faqian; Yu, Jiangzhou // BMC Cancer;11/18/2015, Vol. 15, p1 

    Background: There is limited information about the clinical and biological significance of prostate specific G protein coupled receptor (PSGR) in prostate cancer (PCa) initiation and progression. Here, we evaluated the expression of PSGR protein, studied its diagnostic and...

  • Overexpression of LAPTM4B-35: A Novel Marker of Poor Prognosis of Prostate Cancer. Zhang, Hongtuan; Wei, Qiang; Liu, Ranlu; Qi, Shiyong; Liang, Peihe; Qi, Can; Wang, Andi; Sheng, Bin; Li, Liang; Xu, Yong // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Background: Lysosome-associated protein transmembrane 4b-35 (LAPTM4B-35) is a member of the mammalian 4-tetratransmembrane spanning protein superfamily, which is overexpressed in several solid malignancies. However, the expression of LAPTM4B-35 and its role in the progression of prostate cancer...

  • miR-203 Acts as a Tumor Suppressor Gene in Osteosarcoma by Regulating RAB22A. Yang, Dawei; Liu, Guangpeng; Wang, Kunzheng // PLoS ONE;9/18/2015, Vol. 10 Issue 9, p1 

    microRNAs (miRNAs), small noncoding RNAs of 19–25 nt, play an important roles in the pathological processes of tumorigenesis. The object of this study was to study the expression and function of miR-203 and to found its target gene in osteosarcoma. In our study, we found the expression...

  • Orai1, a Direct Target of microRNA-519, Promotes Progression of Colorectal Cancer via Akt/GSK3β Signaling Pathway. Deng, Wei; Wang, Jin; Zhang, Jun; Cai, Jun; Bai, Zhigang; Zhang, Zhongtao // Digestive Diseases & Sciences;Jun2016, Vol. 61 Issue 6, p1553 

    Background: Orai1, which is involved in store-operated calcium entry, has recently been implicated in cancer progression. However, the role of Orai1 in colorectal cancer (CRC) progression remains unclear.Methods: We used real-time PCR and western blot to measure Orai1...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics